179 filings
Page 4 of 9
8-K
62v870yn trw
16 Mar 20
Entry into a Material Definitive Agreement
4:30pm
8-K
oasgfppq orcwkogq
10 Feb 20
Other Events
4:54pm
8-K
iqf4r597 woeiy
29 Aug 19
Departure of Directors or Certain Officers
4:30pm
8-K
9kafh9wn
29 Aug 19
Entry into a Material Definitive Agreement
6:45am
8-K
a94hye
7 Aug 19
Rexahn Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Update on RX-3117 Development
6:43am
8-K
mgs0jmqiika8 7l
7 Jun 19
Submission of Matters to a Vote of Security Holders
2:19pm
8-K
c0lpabpdap7gngaj
29 May 19
Rexahn Announces Move to Nasdaq
12:56pm
8-K
7asecooo
16 Apr 19
Rexahn and BioSense Global Announce Collaboration and License Agreement for RX-3117 in Greater China
8:03am
8-K
yhhnp cfg
12 Apr 19
Amendments to Articles of Incorporation or Bylaws
8:15am
8-K
h44jr
26 Mar 19
Submission of Matters to a Vote of Security Holders
4:13pm
8-K
iy5kun046cl9n9zaxw
11 Mar 19
Regulation FD Disclosure
6:54am
8-K
zsj5jmii2v8h26v5q
6 Mar 19
Departure of Directors or Certain Officers
4:23pm
8-K
61qw33twx6v9o
1 Mar 19
Rexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors
5:10pm
8-K
na5xe fwq2z
25 Jan 19
Entry into a Material Definitive Agreement
4:51pm
8-K
41ztquf0eg5pgxy0c
22 Jan 19
Rexahn Presents Updated Preliminary Data on RX-3117 in Pancreatic Cancer
4:48pm
8-K
6f5d2k 69a25
3 Dec 18
Rexahn Pharmaceuticals Appoints Gil Price to its Board of Directors
4:53pm
8-K
1wca5 m9rzcvmupbfh
16 Nov 18
Rexahn Pharmaceuticals Announces Leadership Transition
4:45pm
8-K
88w2tx2ek cknqm
19 Oct 18
Entry into a Material Definitive Agreement
9:19am
8-K
ici8xlmef02p
30 Aug 18
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
lh569dl
21 Aug 18
Entry into a Material Definitive Agreement
12:00am